Please login to the form below

Not currently logged in
Email:
Password:

Perrigo

This page shows the latest Perrigo news and features for those working in and with pharma, biotech and healthcare.

Pfizer set to unveil Mylan merger and spin-off

Pfizer set to unveil Mylan merger and spin-off

The merger is likely to have knock-on effects for the other big players in the market, which in addition to Teva include Perrigo and Sandoz.

Latest news

More from news
Approximately 9 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    $35bn. $7.3bn. Valeant. 40. 17.5. -56%. $28bn. ($2.4bn). Perrigo. 90. 78. ... Perrigo, like Teva and Valeant, is seeking to reduce debt. Biotech companies are also selling (or licensing) assets to stay alive.

  • Deal Watch February 2017 Deal Watch February 2017

    The largest of these was Perrigo's divestment to Royalty Pharma of its royalty stream from Biogen's global sales of Tysabri (natalizumab), the multiple sclerosis antibody originally developed by Elan, ... 17, 900. Perrigo/ Royalty Pharma. Tysabri

  • Deal Watch August 2016 Deal Watch August 2016

    In contrast, in 2015 Mylan made a tender offer for Perrigo. ... Sep 15 / Hostile. Mylan. Perrigo. $26bn. Tender offer failed as Mylan shares dropped in value (Teva withdrew bid).

  • Deal Watch November 2015 Deal Watch November 2015

    Perrigo paid a multiple of 3.2x sales for the US rights whereas Tillotts paid 4.1x sales. ... 386. AstraZeneca. Perrigo. Acquisition - asset. Entocort (budesonide) marketed for mild to moderate Crohn's disease.

  • Pharma deals in August 2015 Pharma deals in August 2015

    Hostile takeovers remained a topic of conversation this month as the Perrigo / Mylan saga played on; the vote taken by Mylan's shareholders on 28 August indicated support for the deal ... Perrigo had previously expressed concerns over Mylan's corporate

More from intelligence
Approximately 0 fully matching, plus 20 partially matching documents found.

Latest appointments

  • Perrigo appoints Gerresheimer’s Uwe Rohrhoff as CEO Perrigo appoints Gerresheimer’s Uwe Rohrhoff as CEO

    Generic pharmaceutical company Perrigo has appointed Uwe Rohrhoff, Gerresheimer’s former chief executive officer, as its new CEO. ... Perrigo said that it suspended its search for a replacement CFO during its search for Hendrickson’s successor as CEO.

  • BMS appoints three independent directors BMS appoints three independent directors

    He currently serves as a director at Perrigo Company and Stamps.com, and is the former president of Capital Guardian Trust Company, and global equity portfolio manager at Capital Group.

  • Valeant appoints Joseph Papa to end CEO uncertainty Valeant appoints Joseph Papa to end CEO uncertainty

    Valeant's month-long search for a new chief executive has ended with its selection of Perrigo's Joseph Papa to replace current CEO Michael Pearson in early May. ... He moves to Valeant from his most recent role as chief executive officer and chairman of

  • Perrigo promotes Neil Lister to UK leadership role Perrigo promotes Neil Lister to UK leadership role

    He will head up the firm's UK and Ireland business. Dublin-based Perrigo Company, has promoted Neil Lister to lead its newly-combined UK and Ireland business. ... In this role, he will be responsible for leading both the company's Omega Pharma

  • Keith Webber leaves FDA for Perrigo Keith Webber leaves FDA for Perrigo

    Switches regulatory agency for biopharma company. Perrigo Company has named former US Food and Drug Administration (FDA) employee Keith Webber as head of its regulatory review process. ... The role marks a switch to the industry side of pharma for Webber,

More from appointments
Approximately 3 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • 3 Monkeys Zeno

    If you’d like to know more healthcare@3monkeyszeno.com Or visit; Merck, Bayer, Boehringher Ingelheim, Novartis, Hologic, Netflix, SilverCloud, Advanced Accelerator Applications,  Perrigo.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics